aspirin has been researched along with Branch Vein Occlusion in 36 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In recent-onset branch retinal vein occlusion, no significant difference was found in the final visual acuity between the patients treated by dalteparin or aspirin." | 9.13 | Dalteparin versus aspirin in recent-onset branch retinal vein occlusion: a randomized clinical trial. ( Farahvash, MM; Farahvash, MS; Mirshahi, A; Mohammadzadeh, S; Moradimogadam, M, 2008) |
| "To compare the long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion with that of aspirin." | 9.13 | Long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion. ( Farahvash, MM; Farahvash, MS; Mohammadzadeh, S; Moradimogadam, M, 2008) |
| "The present study assessed the therapeutic effects of dalteparin in patients who had recent onset central retinal vein occlusion (CRVO) as compared with those of acetylsalicylic acid (ASA)." | 9.13 | Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid. ( Farahvash, MS; Moghaddam, MM; Moghimi, S; Mohammadzadeh, S, 2008) |
| "This is a case report of central retinal vein occlusion (CRVO) associated with COVID-19 treated with oral aspirin therapy." | 8.02 | COVID-19-associated central retinal vein occlusion treated with oral aspirin. ( Agrawal, S; Pereira, A; Reddy, NG; Venkatesh, R, 2021) |
| "Since atherosclerosis contributes to the pathophysiology of retinal vein occlusion (RVO), we aimed to assess the effects of aspirin and statins on the visual outcomes of RVO in high-risk patients, whom we define to have hypertension and open-angle glaucoma prior to RVO." | 7.85 | Poor outcomes despite aspirin or statin use in high-risk patients with retinal vein occlusion. ( Matei, VM; Nguyen, C; Xia, JY, 2017) |
| "To describe development of retinal vein occlusion (RVO) in patients anticoagulated with warfarin." | 7.72 | Retinal vein occlusions in patients taking warfarin. ( Browning, DJ; Fraser, CM, 2004) |
| "In recent-onset branch retinal vein occlusion, no significant difference was found in the final visual acuity between the patients treated by dalteparin or aspirin." | 5.13 | Dalteparin versus aspirin in recent-onset branch retinal vein occlusion: a randomized clinical trial. ( Farahvash, MM; Farahvash, MS; Mirshahi, A; Mohammadzadeh, S; Moradimogadam, M, 2008) |
| "To compare the long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion with that of aspirin." | 5.13 | Long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion. ( Farahvash, MM; Farahvash, MS; Mohammadzadeh, S; Moradimogadam, M, 2008) |
| "The present study assessed the therapeutic effects of dalteparin in patients who had recent onset central retinal vein occlusion (CRVO) as compared with those of acetylsalicylic acid (ASA)." | 5.13 | Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid. ( Farahvash, MS; Moghaddam, MM; Moghimi, S; Mohammadzadeh, S, 2008) |
| "This is a case report of central retinal vein occlusion (CRVO) associated with COVID-19 treated with oral aspirin therapy." | 4.02 | COVID-19-associated central retinal vein occlusion treated with oral aspirin. ( Agrawal, S; Pereira, A; Reddy, NG; Venkatesh, R, 2021) |
| "Since atherosclerosis contributes to the pathophysiology of retinal vein occlusion (RVO), we aimed to assess the effects of aspirin and statins on the visual outcomes of RVO in high-risk patients, whom we define to have hypertension and open-angle glaucoma prior to RVO." | 3.85 | Poor outcomes despite aspirin or statin use in high-risk patients with retinal vein occlusion. ( Matei, VM; Nguyen, C; Xia, JY, 2017) |
| "To describe development of retinal vein occlusion (RVO) in patients anticoagulated with warfarin." | 3.72 | Retinal vein occlusions in patients taking warfarin. ( Browning, DJ; Fraser, CM, 2004) |
| "Antiphospholipid syndrome is a rare cause of ocular vaso-occlusive disease, but is associated with significant systemic morbidity and mortality." | 2.48 | Antiphospholipid antibody syndrome. ( Foster, CS; Kruh, JN; Yang, P, 2012) |
| "Retinal vein occlusion is a frequent cause of visual loss for which few effective therapies are available." | 2.46 | Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. ( Ageno, W; Hawel, J; Kovacs, MJ; Lazo-Langner, A, 2010) |
| "Genetic thrombophilia was detected in 13% of patients." | 1.43 | The role of coagulation disorders in patients with retinal vein occlusion. ( Hernández, JL; Napal, JJ; Neila, S; Pérez-Montes, R; Ruiz, S; Sierra, I, 2016) |
| "To investigate risk factors for central retinal vein occlusion (CRVO)." | 1.34 | Central retinal vein occlusion case-control study. ( Bruè, C; Ferrara, DC; Koizumi, H; Spaide, RF, 2007) |
| "Associations between retinal vein thrombosis and other systemic disorders have been well documented, but a comprehensive literature search failed to reveal any report of essential thrombocythemia as a cause of central retinal vein thrombosis." | 1.33 | Retinal vein thrombosis as the presenting symptom of essential thrombocythemia. ( Aithal, S; Huang, YW; Marshak, H; Novetsky, A; Saffra, N; Tache, JE, 2005) |
| "Aspirin was recommended to reduce the risk of future thromboses." | 1.32 | Antiphospholipid antibody syndrome in a six-year-old female patient. ( Hartnett, ME; Laposata, M; Van Cott, E, 2003) |
| " The pathogenesis of cilioretinal arterial obstruction combined with central retinal venous occlusion is not established." | 1.30 | Central retinal vein occlusion combined with occlusion of a cilioretinal artery. A case report. ( Wrigstad, A, 1998) |
| "We report a case of unilateral central retinal vein occlusion resulting from essential thrombocythemia, a rare myeloproliferative disorder with abnormally increased platelet count." | 1.29 | Essential thrombocythemia and central retinal vein occlusion with neovascular glaucoma. ( Townsend-Pico, W; Yoshizumi, MO, 1996) |
| "A 45-year-old man with pernicious anemia presented with sudden loss of vision due to central retinal vein thrombosis, and was found to have anticardiolipin antibodies and a clotting disorder consistent with the presence of a lupus anticoagulant." | 1.28 | Retinal vein thrombosis in a patient with pernicious anemia and anticardiolipin antibodies. ( Froelich, CJ; Heckerling, PS; Schade, SG, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.78) | 18.7374 |
| 1990's | 6 (16.67) | 18.2507 |
| 2000's | 12 (33.33) | 29.6817 |
| 2010's | 16 (44.44) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Venkatesh, R | 1 |
| Reddy, NG | 1 |
| Agrawal, S | 1 |
| Pereira, A | 1 |
| Belcaro, G | 2 |
| Dugall, M | 2 |
| Bradford, HD | 1 |
| Cesarone, MR | 1 |
| Feragalli, B | 2 |
| Gizzi, C | 2 |
| Cotellese, R | 1 |
| Hu, S | 2 |
| Rodriguez, P | 2 |
| Hosoi, M | 2 |
| Dari, ML | 1 |
| Nguyen, C | 2 |
| Wolfensberger, TJ | 1 |
| Pournaras, JA | 1 |
| Chapin, J | 1 |
| Carlson, K | 1 |
| Christos, PJ | 1 |
| DeSancho, MT | 1 |
| Luzzi, R | 1 |
| Ledda, A | 1 |
| Ippolito, E | 1 |
| Corsi, M | 1 |
| Ricci, A | 1 |
| Cornelli, U | 1 |
| Napal, JJ | 1 |
| Neila, S | 1 |
| Pérez-Montes, R | 1 |
| Sierra, I | 1 |
| Ruiz, S | 1 |
| Hernández, JL | 1 |
| Consigli, A | 1 |
| Roquelaure, D | 1 |
| Souteyrand, G | 1 |
| Chizzolini, C | 1 |
| Thumann, G | 1 |
| Chronopoulos, A | 1 |
| Jomni, T | 1 |
| Bellakhal, S | 1 |
| Abouda, M | 1 |
| Abdelaali, I | 1 |
| Douggui, H | 1 |
| Matei, VM | 1 |
| Xia, JY | 1 |
| Stoffelns, BM | 1 |
| Farahvash, MS | 3 |
| Moradimogadam, M | 2 |
| Farahvash, MM | 2 |
| Mohammadzadeh, S | 3 |
| Mirshahi, A | 1 |
| Katsi, V | 1 |
| Tousoulis, D | 1 |
| Chatzistamatiou, E | 1 |
| Androulakis, E | 1 |
| Moustakas, G | 1 |
| Skiadas, I | 1 |
| Tsioufis, C | 1 |
| Antoniades, C | 1 |
| Stefanadis, CI | 1 |
| Kallikazaros, IE | 1 |
| Ageno, W | 4 |
| Cattaneo, R | 1 |
| Manfredi, E | 2 |
| Chelazzi, P | 1 |
| Venco, L | 1 |
| Ghirarduzzi, A | 1 |
| Cimino, L | 1 |
| Filippucci, E | 1 |
| Ricci, AL | 1 |
| Romanelli, D | 1 |
| Incorvaia, C | 1 |
| D'Angelo, S | 1 |
| Campana, F | 1 |
| Molfino, F | 1 |
| Scannapieco, G | 1 |
| Rubbi, F | 1 |
| Imberti, D | 1 |
| Squizzato, A | 2 |
| Bozzato, S | 1 |
| Dentali, F | 1 |
| Lazo-Langner, A | 2 |
| Hawel, J | 1 |
| Kovacs, MJ | 1 |
| Mazinani, B | 1 |
| Plange, N | 1 |
| Walter, P | 1 |
| Hayreh, SS | 1 |
| Podhajsky, PA | 1 |
| Zimmerman, MB | 1 |
| Yang, P | 1 |
| Kruh, JN | 1 |
| Foster, CS | 1 |
| Levy, J | 1 |
| Baumgarten, A | 1 |
| Rosenthal, G | 1 |
| Rabinowitz, R | 1 |
| Lifshitz, T | 1 |
| Hartnett, ME | 1 |
| Laposata, M | 1 |
| Van Cott, E | 1 |
| Browning, DJ | 1 |
| Fraser, CM | 1 |
| Yamamoto, T | 1 |
| Kamei, M | 1 |
| Yokoi, N | 1 |
| Yasuhara, T | 1 |
| Tei, M | 1 |
| Kinoshita, S | 1 |
| Tache, JE | 1 |
| Saffra, N | 1 |
| Marshak, H | 1 |
| Aithal, S | 1 |
| Novetsky, A | 1 |
| Huang, YW | 1 |
| Masood, I | 1 |
| Lippi, G | 1 |
| Franchini, M | 1 |
| Targher, G | 1 |
| Koizumi, H | 1 |
| Ferrara, DC | 1 |
| Bruè, C | 1 |
| Spaide, RF | 1 |
| Moghaddam, MM | 1 |
| Moghimi, S | 1 |
| Yoshizumi, MO | 1 |
| Townsend-Pico, W | 1 |
| Baglivo, E | 1 |
| Dosso, A | 1 |
| Pournaras, C | 1 |
| Etaouil, N | 1 |
| Benyahya, E | 1 |
| Mkinsi, O | 1 |
| Amraoui, A | 1 |
| Wrigstad, A | 1 |
| Mizugaki, M | 1 |
| Hishinuma, T | 1 |
| Matsumura, E | 1 |
| Murai, Y | 1 |
| Yamazaki, T | 1 |
| Yamanobe, S | 1 |
| Tamai, M | 1 |
| Heckerling, PS | 1 |
| Froelich, CJ | 1 |
| Schade, SG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Parnaparin Versus Aspirin in the Treatment of Retinal Vein Occlusion. A Randomized, Double Blind, Controlled Study[NCT00732927] | Phase 3 | 67 participants (Actual) | Interventional | 2002-07-31 | Terminated (stopped due to slow recruitment rate) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for aspirin and Branch Vein Occlusion
| Article | Year |
|---|---|
Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action.
Topics: Aspirin; Drug Evaluation; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Randomized Con | 2010 |
Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials.
Topics: Aspirin; Heparin, Low-Molecular-Weight; Humans; Randomized Controlled Trials as Topic; Retinal Vein | 2010 |
Antiphospholipid antibody syndrome.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; beta 2-Glycoprotein I; Humans; Hyd | 2012 |
5 trials available for aspirin and Branch Vein Occlusion
| Article | Year |
|---|---|
Dalteparin versus aspirin in recent-onset branch retinal vein occlusion: a randomized clinical trial.
Topics: Aspirin; Dalteparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Retinal Vein Occlusion; | 2008 |
Long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion.
Topics: Aspirin; Dalteparin; Female; Fibrinolytic Agents; Humans; Iris; Male; Middle Aged; Neovascularizatio | 2008 |
Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study.
Topics: Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female | 2010 |
Comparative effect of antiplatelet therapy in retinal vein occlusion evaluated by the particle-counting method using light scattering.
Topics: Aged; Aspirin; Epoprostenol; Female; Humans; Light; Male; Middle Aged; Particle Size; Platelet Aggre | 2004 |
Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid.
Topics: Administration, Oral; Aspirin; Dalteparin; Female; Fibrinolytic Agents; Humans; Injections, Subcutan | 2008 |
28 other studies available for aspirin and Branch Vein Occlusion
| Article | Year |
|---|---|
COVID-19-associated central retinal vein occlusion treated with oral aspirin.
Topics: Aspirin; COVID-19; Female; Fluorescein Angiography; Humans; Middle Aged; Retinal Vein Occlusion; SAR | 2021 |
Recurrent retinal vein thrombosis: prevention with Aspirin, Pycnogenol®, ticlopidine, or sulodexide.
Topics: Adult; Aspirin; Female; Fibrinolytic Agents; Flavonoids; Glycosaminoglycans; Humans; Incidence; Male | 2019 |
Systematic treatment of central retinal vein occlusion.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Combined Modality Therapy; Folic Acid; Humans; Lig | 2013 |
Risk Factors and Treatment Strategies in Patients With Retinal Vascular Occlusions.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Female; Humans; Hyperlipidemias; Hypertension; Male; Middle | 2015 |
Recurrence of retinal vein thrombosis with Pycnogenol® or Aspirin® supplementation: a registry study.
Topics: Adult; Aspirin; Female; Fibrinolytic Agents; Flavonoids; Humans; Incidence; Italy; Male; Middle Aged | 2015 |
The role of coagulation disorders in patients with retinal vein occlusion.
Topics: Aged; Antibodies, Antiphospholipid; Anticoagulants; Aspirin; Case-Control Studies; Female; Homocyste | 2016 |
Diagnostic Dilemma in Sequential Branch Retinal Vein and Artery Occlusion.
Topics: Adult; Antibodies, Anticardiolipin; Aspirin; beta 2-Glycoprotein I; Fibrinolytic Agents; Fluorescein | 2015 |
[An atypical presentation of celiac disease: central retinal vein occlusion].
Topics: Adult; Anemia, Iron-Deficiency; Aspirin; Biopsy; Celiac Disease; Diet, Gluten-Free; Female; Humans; | 2015 |
Poor outcomes despite aspirin or statin use in high-risk patients with retinal vein occlusion.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Case-Control Studies; Dose-Response Relati | 2017 |
[Central Retinal Vein Occlusion accompanied by positive testing of serum antineutrophil cytoplasmic antibodies (c-ANCA)].
Topics: Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Aspirin; Combined Modality Therapy | 2008 |
A 31 year old woman with essential hypertension grade III and branch retinal vein occlusion with homozygous C677T MTHFR hyperhomocysteinemia and high Lp(a) levels.
Topics: Adult; Antihypertensive Agents; Aspirin; Female; Humans; Hyperhomocysteinemia; Hypertension; Lipopro | 2010 |
[The value of acetylsalicylic acid in retinal vein occlusion].
Topics: Aspirin; Cardiovascular Diseases; Humans; Macular Edema; Platelet Aggregation Inhibitors; Retinal Ve | 2010 |
Retinal-vein occlusion.
Topics: Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Humans; Retinal Vein Occlusion | 2011 |
Central and hemicentral retinal vein occlusion: role of anti-platelet aggregation agents and anticoagulants.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Dipyridamole; F | 2011 |
Consecutive central retinal artery and vein occlusions in primary antiphospholipid syndrome.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Fluore | 2002 |
Antiphospholipid antibody syndrome in a six-year-old female patient.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; | 2003 |
Retinal vein occlusions in patients taking warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Humans; Male; Middle Aged; Retinal | 2004 |
Retinal vein thrombosis as the presenting symptom of essential thrombocythemia.
Topics: Adult; Aspirin; Diagnosis, Differential; Female; Fibrinolytic Agents; Humans; Retinal Vein Occlusion | 2005 |
Comparative effect of antiplatelet therapy in retinal vein occlusion evaluated by the particle-counting method using light scattering.
Topics: Aspirin; Clopidogrel; Epoprostenol; Humans; Light; Particle Size; Platelet Aggregation; Platelet Agg | 2005 |
Platelets and lipoprotein(a) in retinal vein occlusion: mutual targets for aspirin therapy.
Topics: Apolipoproteins A; Aspirin; Blood Platelets; Humans; Lipoprotein(a); Platelet Activation; Platelet A | 2007 |
Central retinal vein occlusion case-control study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Female; Glaucoma; Humans; | 2007 |
Essential thrombocythemia and central retinal vein occlusion with neovascular glaucoma.
Topics: Adrenergic beta-Antagonists; Antisickling Agents; Aspirin; Bone Marrow; Fluorescein Angiography; Fun | 1996 |
Thrombus and branch retinal vein occlusion.
Topics: Aspirin; Calcium Channel Blockers; Fluorescein Angiography; Fundus Oculi; Humans; Hyperlipidemias; H | 1997 |
Primary antiphospholipid syndrome with retinal vein occlusion. Treatment with acetylsalicylic acid.
Topics: Antiphospholipid Syndrome; Aspirin; Humans; Male; Middle Aged; Retinal Vein Occlusion | 1997 |
Central retinal vein occlusion combined with occlusion of a cilioretinal artery. A case report.
Topics: Adult; Aspirin; Betamethasone; Ciliary Arteries; Drug Therapy, Combination; Fluorescein Angiography; | 1998 |
Consultation section. Cataract surgical problem.
Topics: Aspirin; Cataract; Humans; Hypertension; Male; Middle Aged; Phacoemulsification; Retinal Vein Occlus | 1999 |
Monitoring of the thromboxane A2/prostacyclin ratio in the urine of patients with retinal vascular occlusion through the low-dose-aspirin therapy using the gas chromatography/selected ion monitoring method.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aspirin; Dose-Response Relationship, Drug; Epoprostenol; Female; | 1999 |
Retinal vein thrombosis in a patient with pernicious anemia and anticardiolipin antibodies.
Topics: Anemia, Pernicious; Aspirin; Autoantibodies; Blood Coagulation Factors; Cardiolipins; Humans; Hypopr | 1989 |